Annual report pursuant to Section 13 and 15(d)

SUBSEQUENT EVENTS (Details)

v3.20.4
SUBSEQUENT EVENTS (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Feb. 28, 2021
Jan. 31, 2021
Dec. 31, 2020
Subsequent event      
Subsequent Event [Line Items]      
Upfront payment received $ 125.0    
Subsequent event | Development and regulatory milestones by non-CNS disease products      
Subsequent Event [Line Items]      
Contingent payments 330.0    
Subsequent event | Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis      
Subsequent Event [Line Items]      
Contingent payments 100.0    
Subsequent event | Development and regulatory milestones by CNS disease products      
Subsequent Event [Line Items]      
Contingent payments 255.0    
Subsequent event | Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis      
Subsequent Event [Line Items]      
Contingent payments $ 150.0    
fostamatinib | Subsequent event      
Subsequent Event [Line Items]      
Award proceeds for clinical trial   $ 16.5  
R552 | Subsequent event      
Subsequent Event [Line Items]      
Company's percentage of development costs 20.00%    
R552 | Subsequent event | Maximum      
Subsequent Event [Line Items]      
Funding commitment $ 65.0    
Collaborative arrangement      
Subsequent Event [Line Items]      
Contingent payments     $ 607.2
License agreement with unrelated third party | Subsequent event      
Subsequent Event [Line Items]      
One-time fee received from license rights granted $ 4.0